- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Onesource Specialty Pharma Limited — Updates, 24-01-2026: General Updates
24-01-2026 | 01:09 pm
24-01-2026 | 01:09 pm
OneSource's Q3FY26 revenue fell 26% to ₹290.3 Cr, EBITDA down 88% to ₹17.3 Cr, hit by semaglutide approval delays. Reaffirmed FY28 guidance for $400M organic/$500M with acquisitions (correcting unit error). Biologics interest and order book strong.
No comments yet. Be the first to comment!